Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: An Indian experience

APLAR Journal of Rheumatology

Volumn 7, Issue 2, 2004, Pages 108-116

  Chopra, Arvind ^a,f   Bichile, L ^b   Rajadhyaksha, A G ^b   Gadgil, D ^c   Maroli, S ^d   Goregaonkar, A B ^d   Dhaon, B K ^e  

^a Bharati Vidyapeeth's Medical College   (India)

^b KEM HOSPITAL   (India)

^c Unichem Laboratories Ltd   (India)

^d LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

^e MAULANA AZAD MEDICAL COLLEGE   (India)

^f Baba House   (India)

Author keywords

Drug trials; Meloxicam; NSAID; Osteoarthritis knee; Rheumatoid arthrits

Indexed keywords

DICLOFENAC; MELOXICAM; PARACETAMOL; PIROXICAM;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSURIA; FEMALE; HEMATURIA; HUMAN; HYPOTHESIS; INDIAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; VOMITING;

EID: 23444434528     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2004.00070.x     Document Type: Article

References (39)

1. Vane JR (1996) Introduction: mechanism of action of NSAIDs. Br J Rheumatol 35, 1-3.
2. Lipsky PE, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LBA (1998) The classification of cyclooxygenase inhibitors. J Rheumatol 25, 2298-302.
3. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA (2000) Current Comment: Basic biology and clinical application of specific cyclo-oxygenase-2 inhibitors. Arthritis Rheum 1, 4-13.
4. Garcia Rodriquez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343, 769-72.
5. Langman MJS, Weil J, Wainwright P, et al. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343, 1075-8.
6. Singh G, Ramay DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1991) Gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115, 787-96.
7. Jackson LM, Hawkey CJ (2000) COX-2 selective non-steroidal anti-inflammatory drugs. Do they really offer any advantages? Drugs 59, 1207-16.
8. Machlis BK, Klostermeyer BS (1999) The cyclo-oxygenase-2 inhibitors: safety and effectiveness. The Ann Pharmacotherapy 33, 979-87.
9. Turck D, Roth W, Busch U (1996) A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35, 13-6.
10. Engelhardt G (1996) Pharmacology of meloxicam a new non-steroidal anti-inflammatory drug with an improved safety profiles through preferential inhibition of COX-2. Br J Rheumatol 35, 4-12.
11. Barner A (1996) Review of clinical trials and benefit/risk ratio of meloxicam. Scan J Rheumatol 25, 29-37.
12. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. (1996) A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg and naproxen 750 mg in patients with rheumatoid arthritis. Br J Rheumatol 35, 17-21.
13. Huskisson EC, Ghozlan R, Kurthen R, Degner FL, Bluhmki E (1996) Long terms study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 35, 22-8.
14. Hosie J, Distel M, Bluhmki E (1996) Meloxicam in osteoarthritis: a 6-month double blind comparison with diclofenac sodium. Br J Rheumatol 35(Suppl 1), 22-8.
15. Hawkey C, Kahan A, Steinbruck K, et al. (1998) and the International MELISSA study Group. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 37, 937-45.
16. Dequeker J, Hawkey C, Kahan A et al. (1998) Improvement in gastrointestinal tolerability of the selective cydooxygenase (COX)-2 inhibitor, meloxicam compared with piroxicam: results of the safety and efficacy large scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37, 946-51.
17. US Department of Health and Human Services. (April 1988) Guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drug (adults and children). US Department of Health and Human Services. Public Health Service, Food and Drug Administration, Washington, DC, 2-11,12-15,29-35.
18. Bellamy N (1993) Osteoarthritis. In: Bellamy N (ed.) Musculoskeletal clinical metrology. Boston: Kluwer Academic Publishers, Boston, 169-76.
19. Felson DT, Anderson JJ, Boers M, et al. (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36, 729-40.
20. Chopra A, Lavin P, Patwardhan B, Chitre D (2000) Randomized double blind trial of an Ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 27, 1365-72.
21. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
22. Hochberg MC, Chang RW, Dwosh I (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35, 498-502.
23. Chopra A, Gore A, Paranjape S, Edmonds J (1996) Modified Health Assessment Questionnaire: an Indian study for validity and relevance (Abstract). Abstracts and Program of the 8th APLAR Congress, Melbourne, Australia April 21-25, 1996. ICMS Pty Ltd, Melbourne, 87 (323).
24. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23, 137-45.
25. Altman R, Asch E, Bloch G, et al. (1986) Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29, 1039-49.
26. Bellamy N, Goldsmith CH, Campbell J, Still LW (1988) Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant measures to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15, 1833-40.
27. Chopra A, Lavin P, Chitre D, Patwardhan B (1998) A clinical study of an Ayurvedic (Asian Indian) medicine in OA, knees (Abstract). Arthritis Rheum 41, S198.
28. Chopra A (2000) Ayurvedic medicine and arthritis. Rheum Dis Clin North Am 26, 133-44.
29. Huskisson EC, Narjes H, Bluhmki E (1994) Efficacy and tolerance of meloxicam a new NSAID, in daily oral doses of 15 30 and 60 mg in comparison to 20-mg piroxicam in patients with rheumatoid arthritis (abstract). Scand J Rheumatol 98 (Suppl), abstract 115.
30. Bellamy N, Carette S, Ford PM, et al. (1992) Osteoarthritis antirheumatic drug trials III, Setting the delta for clinical trials-results of a consensus development (Delphi) exercise. J Rheumatol 19, 451-7.
31. Scott DL, Roden S, Marshall T, Kendall MJ (1982) Variations in responses to non-steroidal anti-inflammatory drugs. Br J Clinical Pharmacol 14, 691-4.
32. Simon LS, Strand V (1997) Clinical response to non-steroidal anti-inflammatory drugs. Arthritis Rheum 40, 1940-3.
33. Walker JS, Sheather RBB, Cormody JJ, Vial JH, Day RO (1997) Non-steroidal anti-inflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of 'responders' and 'non-responders'. Arthritis Rheum 40, 1944-54.
34. Reginster JY, Distel M, Bluhmki E (1996) A double blind three week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 35, 17-21.
35. Distel M, Mueller C, Bluhmki E, Fries J (1996) Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 35, 61-8.
36. Willoughby DA, Moore AR, Colville Nash PR (2000) COX-1 COX-2, COX-3 and the future treatment of chronic inflammatory diseases. Lancet 355, 646-8.
37. Peterson WL, Cryer B (1999) COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 282, 1961-3.
38. Brooks P, Emery P, Evans JF et al. (1999) Interpreting the clinical significance of the differential inhibition of cyclooxygenase-2. Rheumatology 38, 779-88.
39. Emery P (1996) Clinical implications of selective COX-2 inhibition. Scand J Rheumatol 25, 23-8.